Searchable abstracts of presentations at key conferences in endocrinology

ea0072p3 | (1) | UKINETS2020

Circulating biomarkers to predict progression-free survival in patients with neuroendocrine tumours received 177Lu-DOTATATE

Chen Luohai , Gnanasegaran Gopinath , Mandair Dalvinder , Toumpanakis Christos , Caplin Martyn , Navalkisoor Shaunak

Background: 177Lu-DOTATATE is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few circulating biomarkers are available to predict progression-free survival (PFS) of patients received 177Lu-DOTATATE.Materials and methods: Clinicopathological data and data of baseline circulating biomarkers including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), e...

ea0094oc2.2 | Endocrine Cancer and Late Effects | SFEBES2023

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes – A single centre retrospective analysis of experience at an ENETS Centre of Excellence

Mansukhbhai Shekhda Kalyan , Armeni Eleni , Hayes Aimee , Navalkissoor Shaunak , Mandair Dalvinder , Xu Yiwang , Yu Dominic , Quigley Ann-Marie , Gnanasegaran Gopinath , Toumpanakis Christos , Caplin Martyn , Khoo Bernard

Introduction: Metastatic phaeochromocytomas (PCC) and paragangliomas (PGL), collectively known as metastatic PPGL (mPPGL), represent uncommon neuroendocrine tumours for which no standardized treatment guidelines exist. The emerging therapeutic modality employing 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) has exhibited favourable tolerability in the management of these patients.Methods: In this...